A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug Treatment
- Conditions
- HIV Infections
- Registration Number
- NCT00006152
- Brief Summary
The purpose of this study is to see if adding 1 or 2 drugs to the anti-HIV therapy of patients whose HIV levels increased while taking their anti-HIV drugs can lower viral load (amount of HIV in the blood) and keep it low up to Week 24. (This study has been changed. Previously, only patients whose levels increased on their first round of anti-HIV drugs were being studied.) Anti-HIV drug treatments that contain a combination of 3 or more drugs can lower HIV levels, raise CD4 cell counts, and improve survival. Unfortunately, many patients "fail" their anti-HIV drug treatment when their HIV levels go above 500 copies/ml. Usually the next step is to switch the patient to different anti-HIV drugs. Doctors would like to see whether adding 1 or 2 different drugs to the "failed" treatment also can lower HIV levels. Adding 1 or 2 drugs might be better than switching all of the drugs since patients who take many different drugs can develop drug-resistant HIV. (This study has been changed. Previously, only patients taking protease inhibitors (PI) whose levels increased on their first round of anti-HIV drugs were being studied.)
- Detailed Description
Successful therapy following viral rebound has been problematic. Intensification of the existing regimen by adding 1 or 2 drugs generally has been avoided. However, successfully adding new drugs to an existing regimen would be advantageous since it would expose the patient to fewer antiretroviral agents in the overall treatment course. Recent evidence suggests that a significant proportion of patients who experience viral rebound while receiving a protease inhibitor (PI) actually have viral rebound with a PI-sensitive virus. Other studies have shown that treatment decisions based on resistance assays result in better virologic outcomes. This trial examines further the effect of resistance assay-directed intensification of a PI-containing antiretroviral regimen on viral load. \[AS PER AMENDMENT 04/03/01: The antiretroviral regimen need not contain a protease inhibitor.\]
Patients are stratified by baseline plasma HIV-1 RNA levels (5,000 copies/ml or less versus greater than 5,000 copies/ml). Patients undergo phenotypic drug resistance testing prior to study entry. Based on the phenotypic results, patients are \[AS PER AMENDMENT 11/9/00: selectively\] randomized equally to 1 of 3 \[AS PER AMENDMENT 11/9/00: 1 of 2\] intensification strategies while remaining on their current, initial \[AS PER AMENDMENT 11/9/00: (background)\] antiretroviral therapy (ART). \[AS PER AMENDMENT 04/03/01: ART need not be initial.\] A patient is excluded from randomization to an arm if that arm contains a drug to which the patient has phenotypic resistance. Arm A adds abacavir (ABC). Arm B adds amprenavir (APV) \[AS PER AMENDMENT 11/9/00: and ritonavir (RTV)\]. Arm C adds didanosine (ddI) plus hydroxyurea (HU). \[AS PER AMENDMENT 11/9/00: Arm C has been discontinued.\] A patient's HIV must be sensitive to at least 3 drugs. \[AS PER AMENDMENT 11/9/00: Each patient must be taking at least 3 drugs to which his/her HIV isolate is sensitive, including ABC or APV and at least 2 other drugs that are part of the current, initial (background) ART. If phenotypic resistance testing at screening indicates resistance to a nucleoside reverse transcriptase inhibitor (NRTI) drug in the patient's current, initial (background) ART, then the local investigator may choose to discontinue that drug. However, the patient and local investigator may choose to continue the drug but it will not be considered an active drug per this protocol.\] \[AS PER AMENDMENT 04/03/01: ART need not be initial.\] Patients have regular clinic visits for physical exams and blood tests, including CD4 and CD8 cell counts, plasma HIV-1 RNA assays, and tests for pharmacokinetic variability. In the event of viral rebound of 500 copies/ml or more at Week 12 or later, phenotypic/genotypic drug resistance is assayed. In addition, phenotypic drug resistance is assayed at the primary endpoint (Week 24) and at the end of treatment (Week 48) on all patients.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 42
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (13)
Beth Israel Deaconess - West Campus
🇺🇸Boston, Massachusetts, United States
Univ of Texas Galveston
🇺🇸Galveston, Texas, United States
Univ of Southern California / LA County USC Med Ctr
🇺🇸Los Angeles, California, United States
Univ of California, San Diego
🇺🇸San Diego, California, United States
Northwestern Univ Med School
🇺🇸Chicago, Illinois, United States
Univ of Colorado Health Sciences Ctr
🇺🇸Denver, Colorado, United States
Julio Arroyo
🇺🇸West Columbia, South Carolina, United States
Univ of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
The CORE Ctr
🇺🇸Chicago, Illinois, United States
St Louis Regional Hosp / St Louis Regional Med Ctr
🇺🇸Saint Louis, Missouri, United States
Beth Israel Med Ctr
🇺🇸New York, New York, United States
Univ of North Carolina
🇺🇸Chapel Hill, North Carolina, United States
Duke Univ Med Ctr
🇺🇸Durham, North Carolina, United States